PHARMA - Relationships

Relationships Table

Entities - Color - Target Drug Disease Lo Med Hi
Word 1
Word 1 Count
CAT1
CAT2
Word 2
Word 2 Count
Co-occurrence
Occurence-Centile
Correlation
Overlap-Metric
G-Metric
Cancer 1,053,491 Disease Target EPHA2 532 239 0.01 -0.74 0.45 0.59
Cancer 1,053,491 Disease Target Kallikrein-6 79 35 0.00 -0.75 0.44 0.58
Cancer 1,053,491 Disease Disease Lung Carcinoma 13,423 5,796 0.05 -0.75 0.43 0.63
Cancer 1,053,491 Disease Disease Carcinoma Squamous Cell 47 20 0.00 -0.76 0.43 0.57
Cancer 1,053,491 Disease Target ERBB3 1,154 481 0.01 -0.76 0.42 0.60
Cancer 1,053,491 Disease Drug Doxorubicin 28,033 11,365 0.07 -0.77 0.41 0.64
Cancer 1,053,491 Disease Drug Aloxi (Palonosetron hydrochloride)- FDA 10 4 0.00 -0.77 0.40 0.56
Cancer 1,053,491 Disease Target AKT3 293 117 0.01 -0.77 0.40 0.58
Cancer 1,053,491 Disease Disease Carcinoma Prostate 68 27 0.00 -0.78 0.40 0.57
Cancer 1,053,491 Disease Disease Neutropenia 25,934 9,960 0.06 -0.78 0.38 0.64
Cancer 1,053,491 Disease Target Insulin-Like Growth Factor 1 Receptor 1,052 405 0.01 -0.78 0.38 0.59
Cancer 1,053,491 Disease Target CHK2 1,391 533 0.01 -0.79 0.38 0.60
Cancer 1,053,491 Disease Disease Fibrocystic Breast Disease 173 65 0.00 -0.79 0.38 0.58
Cancer 1,053,491 Disease Disease Carcinoma Head 24 9 0.00 -0.79 0.38 0.57
Cancer 1,053,491 Disease Drug Dromostanolone 8 3 0.00 -0.79 0.38 0.56
Cancer 1,053,491 Disease Target Aurora A kinase 318 118 0.01 -0.79 0.37 0.58
Cancer 1,053,491 Disease Target Multidrug Resistance Protein 1 495 183 0.01 -0.79 0.37 0.59
Cancer 1,053,491 Disease Drug Aredia (Pamidronate Disodium)- FDA 14 5 0.00 -0.80 0.36 0.56
Cancer 1,053,491 Disease Drug Doxorubicin Hydrochloride 581 204 0.01 -0.81 0.35 0.59
Cancer 1,053,491 Disease Target BRSK1 20 7 0.00 -0.81 0.35 0.56
Cancer 1,053,491 Disease Target Equilibrative Nucleoside Transporter 1 211 71 0.00 -0.81 0.34 0.58
Cancer 1,053,491 Disease Target CHK1 2,044 681 0.01 -0.82 0.33 0.60
Cancer 1,053,491 Disease Target AKT2 873 284 0.01 -0.82 0.33 0.59
Cancer 1,053,491 Disease Drug Doxorubicin Analogue 25 8 0.00 -0.82 0.32 0.56
Cancer 1,053,491 Disease Target Glutathione S-Transferase Theta-1 70 22 0.00 -0.83 0.31 0.57
Cancer 1,053,491 Disease Target Epiregulin 291 91 0.01 -0.83 0.31 0.58
Cancer 1,053,491 Disease Drug Aldara (Imiquimod)- FDA 36 11 0.00 -0.83 0.31 0.56
Cancer 1,053,491 Disease Disease Arthralgia Syndrome 23 7 0.00 -0.83 0.30 0.56
Cancer 1,053,491 Disease Disease Genital Warts 1,791 540 0.01 -0.84 0.30 0.59
Cancer 1,053,491 Disease Drug Aranesp (Darbepoetin Alfa)- FDA 20 6 0.00 -0.84 0.30 0.56
Cancer 1,053,491 Disease Drug Drometrizole 10 3 0.00 -0.84 0.30 0.56
Cancer 1,053,491 Disease Target Urokinase-Type Plasminogen Activator 3,939 1,166 0.02 -0.84 0.30 0.60
Cancer 1,053,491 Disease Target BRK 236 70 0.00 -0.84 0.30 0.57
Cancer 1,053,491 Disease Target CAPG 85 25 0.00 -0.84 0.29 0.57
Cancer 1,053,491 Disease Target beta-Cellulin 17 5 0.00 -0.84 0.29 0.56
Cancer 1,053,491 Disease Target EPHB4 329 94 0.01 -0.85 0.29 0.58
Cancer 1,053,491 Disease Target AP2M1 7 2 0.00 -0.85 0.29 0.56
Cancer 1,053,491 Disease Target CXCL14/BRAK 7 2 0.00 -0.85 0.29 0.56
Cancer 1,053,491 Disease Drug Amaryl (Glimepiride)- FDA 7 2 0.00 -0.85 0.29 0.56
Cancer 1,053,491 Disease Target CCN5 57 16 0.00 -0.85 0.28 0.56
Cancer 1,053,491 Disease Target Ret Proto-Oncogene 1,005 281 0.01 -0.85 0.28 0.58
Cancer 1,053,491 Disease Target Hypoxia-Inducible Factor 1-Alpha 923 257 0.01 -0.85 0.28 0.58
Cancer 1,053,491 Disease Target Cytokeratin 8 587 162 0.01 -0.85 0.28 0.58
Cancer 1,053,491 Disease Target ERBB4 994 273 0.01 -0.85 0.27 0.58
Cancer 1,053,491 Disease Target Collapsin Response Mediator Protein-1 30 8 0.00 -0.86 0.27 0.56
Cancer 1,053,491 Disease Target Glutathione S-Transferase A3 15 4 0.00 -0.86 0.27 0.56
Cancer 1,053,491 Disease Disease Benign Prostatic Hyperplasia 10,026 2,638 0.03 -0.86 0.26 0.61
Cancer 1,053,491 Disease Disease Basal Cell Carcinoma 7,953 2,086 0.02 -0.86 0.26 0.60
Cancer 1,053,491 Disease Target ACVR1B 23 6 0.00 -0.86 0.26 0.56
Cancer 1,053,491 Disease Target AXL 633 165 0.01 -0.86 0.26 0.58